4-Chloro-5-iodo-2-methylpyridine | 1092287-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Chloro-5-iodo-2-methylpyridine
• CAS: 1092287-21-2
• 化学式: C₆H₅ClIN
• 分子量: 253.47
• InChiKey: OMPQIXIZXUOZPM-UHFFFAOYSA-N

物化性质

• 沸点：
  254.2±35.0 °C(Predicted)
• 密度：
  1.906±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES
  申请人：GRÜNENTHAL GMBH

  公开号：US20150166505A1

  公开（公告）日：2015-06-18

  The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

  这项发明涉及以吡唑基为基础的羧酰胺化合物，其作为ICRAC抑制剂有用，涉及含有这些化合物的药物组合物以及使用这些化合物治疗和/或预防疾病和/或疾病的方法，特别是炎症性疾病和/或炎症性疾病。
• 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20160115169A1

  公开（公告）日：2016-04-28

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及一种新型的6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体亚型2（“mGluR2”）的负向变构调节剂（NAMs）。本发明还涉及包含这些化合物的制药组合物、制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗与代谢型受体亚型2有关的疾病。
• 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP3004107B1

  公开（公告）日：2017-05-10
• SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190055257A1

  公开（公告）日：2019-02-21

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.